Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.
Nivolumab
prognostic factor
recurrent or metastatic head and neck carcinoma
squamous cell carcinoma
treatment-related adverse events
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Sep 2019
06 Sep 2019
Historique:
received:
13
07
2019
revised:
03
09
2019
accepted:
06
09
2019
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
11
9
2019
Statut:
epublish
Résumé
Recently, a global phase III study demonstrated that nivolumab markedly improved patient outcomes in recurrent or metastatic head and neck carcinoma (RMHNC). However, the efficacy of nivolumab in patients who are ineligible for clinical trials is unknown. We investigated nivolumab efficacy in real-world patients and prognostic factors associated with the response to nivolumab. This study was conducted at 11 institutes associated with Kyoto University and its Affiliated Hospitals-Head and Neck Oncology Group. In total, 93 patients with RMHNC who received nivolumab between May 2017 and May 2018 were retrospectively reviewed. Objective response rate (ORR), overall survival, and progression-free survival (PFS) were evaluated. Univariate and multivariate analyses were performed to identify prognostic factors. The ORRs in patients with squamous cell carcinoma (SCC) and non-SCC were 21.8% and 0%, respectively. In patients with SCC and non-SCC, the 1-year PFS rates were 28.7% and 8.9%, respectively. The hazard ratio (HR) for risk of PFS events (SCC versus non-SCC) was 2.28 (95% confidence interval: 1.21-4.1; log-rank
Identifiants
pubmed: 31500103
pii: cancers11091317
doi: 10.3390/cancers11091317
pmc: PMC6770631
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncoimmunology. 2015 May 28;4(11):e1046028
pubmed: 26451318
Oncoimmunology. 2014 May 14;3:e28780
pubmed: 25083318
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Eur J Cancer. 2019 Mar;109:21-27
pubmed: 30682533
Head Neck. 2018 Feb;40(2):406-416
pubmed: 29206324
Auris Nasus Larynx. 2019 Oct;46(5):813-817
pubmed: 30442438
Jpn J Clin Oncol. 2015 Sep;45(9):884-91
pubmed: 26142437
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Oral Oncol. 2018 Dec;87:204-206
pubmed: 30539728
Head Neck. 2018 Apr;40(4):676-686
pubmed: 29171929
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Head Neck. 2018 Mar;40(3):614-621
pubmed: 29159978
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Oncologist. 2017 Oct;22(10):1232-1237
pubmed: 28652280
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Head Neck. 2017 Feb;39(2):201-205
pubmed: 27898198
Head Neck. 2018 Sep;40(9):1889-1896
pubmed: 29952099
Head Neck. 2017 May;39(5):833-839
pubmed: 28263449
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Eur J Cancer. 2019 Feb;108:25-32
pubmed: 30605822
J Immunother. 2016 Nov/Dec;39(9):367-372
pubmed: 27741091
Oncoimmunology. 2017 May 19;6(7):e1329071
pubmed: 28811971
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Head Neck. 2016 Jul;38(7):987-92
pubmed: 27015108
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Curr Oncol. 2018 Aug;25(4):e291-e297
pubmed: 30111974
Crit Rev Oncol Hematol. 2017 Apr;112:136-152
pubmed: 28325255
Head Neck. 2018 Jan;40(1):170-181
pubmed: 29076227
Head Neck. 2019 Feb;41(2):269-280
pubmed: 30548929
Oncoimmunology. 2017 Nov 27;7(3):e1395996
pubmed: 29399393
Auris Nasus Larynx. 2017 Aug;44(4):375-380
pubmed: 28325607
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219